Bank Of New York Mellon Corp Sutro Biopharma, Inc. Transaction History

Bank Of New York Mellon Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $1.29 Million - $1.93 Million	238,705 New	238,705 $1.93 Million
Q3 2022 Nov 14, 2022	BUY	$5.17 - $7.11 $97,661 - $134,307	18,890 Added 13.79%	155,873 $865,000
Q2 2022 Aug 15, 2022	SELL	$3.41 - $8.95 $46,495 - $122,033	-13,635 Reduced 9.05%	136,983 $714,000
Q1 2022 May 11, 2022	BUY	$7.78 - $15.31 $7,803 - $15,355	1,003 Added 0.67%	150,618 $1.24 Million
Q4 2021 Feb 11, 2022	SELL	$14.25 - $23.53 $246,012 - $406,221	-17,264 Reduced 10.35%	149,615 $2.23 Million
Q3 2021 Nov 12, 2021	BUY	$16.88 - $22.38 $224,217 - $297,273	13,283 Added 8.65%	166,879 $3.15 Million
Q2 2021 Aug 11, 2021	BUY	$18.03 - $23.82 $941,129 - $1.24 Million	52,198 Added 51.48%	153,596 $2.86 Million
Q1 2021 May 13, 2021	BUY	$20.29 - $27.54 $11,829 - $16,055	583 Added 0.58%	101,398 $2.31 Million
Q4 2020 Feb 09, 2021	BUY	$10.16 - $23.98 $400,832 - $946,058	39,452 Added 64.29%	100,815 $2.19 Million
Q3 2020 Nov 12, 2020	BUY	$7.44 - $13.15 $85,247 - $150,672	11,458 Added 22.96%	61,363 $616,000
Q2 2020 Aug 12, 2020	BUY	$7.24 - $11.05 $152,409 - $232,613	21,051 Added 72.96%	49,905 $387,000
Q1 2020 May 06, 2020	BUY	$6.19 - $12.16 $99 - $194	16 Added 0.06%	28,854 $294,000
Q3 2019 Nov 07, 2019	SELL	$7.91 - $11.76 $12,924 - $19,215	-1,634 Reduced 5.36%	28,838 $262,000
Q2 2019 Aug 12, 2019	BUY	$9.69 - $12.23 $151,076 - $190,677	15,591 Added 104.77%	30,472 $347,000
Q1 2019 May 14, 2019	BUY	$8.8 - $11.87 $130,952 - $176,637	14,881 New	14,881 $169,000

136

62.4M

77.1K

31.4K

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $131M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.